Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol vs Amlodipine in Masked Hypertension
NCT04121299Phase 3Withdrawn
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2021
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of carvedilol in hypertension (HTN) (2 arms), sponsored by University of Alabama at Birmingham. Primary endpoints: 24-hour Ambulatory Blood Pressure at 4 weeks, Awake Ambulatory Blood Pressure at 4 weeks and 1 more. Planned start Jul 2021; status: withdrawn.
02
Drugs
carvedilol
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04121299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04121299.